• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

The Next Top 5 FDA-Cleared Apps for Primary Care

News
Slideshow

A personal EKG monitor, an app that wirelessly connects to a smart thermometer, and 3 more FDA-cleared apps for primary care. 

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Dupilumab Cardiometabolic Safety in Real-World Study Supports Clinical Trial Evidence / image credit University of Lubeck, Germany

Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence

Grace Halsey
February 21st 2025
Article

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose / image credit: ©New Africa/AdobeStock

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose

Sydney Jennings
February 13th 2025
Article

Your daily dose of the clinical news you may have missed.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Heart Disease Remains Leading Cause of Death in US: Daily Dose / image credit: ©New Africa/AdobeStock

Heart Disease Remains Leading Cause of Death in US: Daily Dose

Sydney Jennings
February 11th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

Patient Care Editorial Staff
February 10th 2025
Article

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

© 2025 MJH Life Sciences

All rights reserved.